Nautilus Biotechnology Inc Dossier - Source-backed chat

Nautilus Biotechnology Inc

NAUTNASDAQ

SectorHealth Care

IndustryLife Sciences Tools & Services

Beta (adjusted)0.89

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.57Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $199.5M

Enterprise Value $186.3M

Shares Outstanding 127M diluted

Next Earnings Date27 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nautilus Biotechnology is a pre-commercial life sciences company pioneering a single-molecule proteomics platform (Nautilus Voyager) designed to democratize access to the proteome. While the company possesses a robust balance sheet with $143.4 million in cash and investments and zero debt, it remains pre-revenue and is burning cash to fund its development. The year 2026 represents a pivotal transition period from pure research to commercial readiness, highlighted by the launch of its Iterative Mapping Early Access Program and plans for a commercial launch in late 2026. Given the high execution risks, intense competition from established players, and a multi-year horizon to meaningful commercial adoption, a Hold recommendation is warranted until tangible proof of commercial traction and platform reproducibility is established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$4.00

High · most bullish analyst$4.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

Technical hurdles or supply chain disruptions delay the planned late 2026 commercial launch or early 2027 customer installations, severely damaging investor confidence. Established competitors (such as Thermo Fisher/Olink or Quantum-Si) capture the market, limiting Nautilus's customer funnel. Rapid cash burn depletes reserves faster than anticipated, forcing the company to raise capital under highly dilutive terms or at a depressed valuation.

Base CaseCentral scenario

$3.0050%

Nautilus executes steadily against its commercialization roadmap, placing beta units in late 2026 and initiating customer installations in early 2027. The company achieves its modest 2026 revenue target of ~$0.5 million, primarily driven by early access engagements and grants. Operating expenses are managed prudently, maintaining the cash runway through 2027. However, stock performance remains highly sensitive to technical milestones and broader market sentiment toward pre-revenue biotech firms.

Bull CaseUpside scenario

$4.0030%

The commercial launch of the Nautilus Voyager platform in late 2026 succeeds, driving strong pre-orders and rapid customer installations in early 2027. Differentiated capabilities in quantifying Tau proteoforms and oncology-focused assays attract major biopharma partnerships, validating the platform's utility in drug discovery and clinical diagnostics. High-margin recurring consumable sales ('razor-and-blade' model) accelerate the path to profitability, and the company successfully extends its cash runway beyond 2027 without dilutive financing.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with $143.4 million in cash, cash equivalents, and investments as of March 31, 2026, and zero debt.
Pioneering single-molecule proteome analysis technology capable of delivering extreme sensitivity and scale to unlock the complex proteoform landscape.
Disciplined financial management, demonstrated by a 14% year-over-year reduction in operating expenses in Q1 2026.
Strategic commercial progress, including the hiring of experienced sales leadership and securing Baylor College of Medicine as the first named Early Access Program customer.

Key Investment Risks

Pre-revenue status with no commercial product sales, making the company entirely dependent on successful future platform commercialization.
Significant cash burn ($12.8 million in Q1 2026) with a finite cash runway extending only through 2027.
High execution and technical risks associated with transitioning from a development-stage life sciences company to commercial operations.
Intense competition from established proteomics and genomics platforms, some of which possess significantly greater commercial scale and distribution networks.

Thesis Invalidation Triggers

Any material delay in the planned late 2026 commercial launch or early 2027 customer installations.
Failure to achieve the projected $0.5 million in full-year 2026 revenue due to further recognition delays.
An unexpected acceleration in quarterly cash burn that shortens the cash runway to mid-2027 or earlier.
Inability to secure additional named customers or biopharma collaborations for the Early Access Program.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.